“Theoretically smaller vials make sense in the normal course of practice. White House officials have told state officials for months that they are talking to vaccine makers about smaller vials. Vaccine makers would need to secure hundreds of millions of smaller vials in a global glass market that was already experiencing shortages before the coronavirus emerged. AstraZeneca, for instance, took months to find a new home for vaccine production after it was booted from a Maryland facility this spring because of contamination issues. And while U.S. doctors clamor for smaller vials, the bigger packaging is still ideal for meeting the expansive global demands, said Krishna Udayakumar, director of the Duke Global Health Innovation Center.